Abstract
Deucravacitinib (SOTYKTU (TM)) is a tyrosine kinase 2 (TYK2) inhibitor that expands the availability of effective oral treatments for the management o......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
